Stocks in play: Oncolytics Biotech® Inc.
Presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The second describes pelareorep's ability to induce the expansion of tumor-infiltrating lymphocytes (TILs) across multiple cancers and the correlation between TIL expansion and tumor response. Oncolytics Biotech® Inc. shares T.ONC are trading unchanged at $1.45.
Read:
Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference
AI's Energy Challenge: Tech Giants Innovate to Preserve Global Electricity Grids
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024
Big Players Lining Up to Secure Critical Supplies of Nickel Despite Price Drop
Agritech Market Boom: AI, IoT, and Biologicals Drive Growth to $49.2 Billion by 2031